Capivasertib:the Breakthrough Cancer Treatment of the Decade's

Capivasertib (TRUQAP), a novel oral AKT inhibitor, targets the PI3K/AKT/mTOR pathway to overcome tumour resistance in advanced breast cancer.Capivasertib has a unique pyrrolopyrimidine derivative structure and is a highly strong ATP-competitive inhibitor of all three AKT isoforms (AKT1, AKT2, and AKT3).This article provides a thorough examination of capivasertib's synthesis, mechanisms of action, physical and chemical properties, and preclinical and clinical efficacy.Its advantages over existing treatments, possible adverse effects, and prospective use in combination therapy are examined.We also examine possible future paths for managing resistance, optimising the therapeutic advantages of capivasertib, and selecting the best patients using biomarkers.Preclinical research has demonstrated the potential of capivasertib in conjunction with endocrine therapy and anti-HER2 drugs. Its clinical importance is highlighted by the FDA's recent approval of TRUQAP in conjunction with Faslodex in November 2023 for advanced HR-positive and HER2-negative breast cancer.